Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Short Interest Update

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) was the target of a large drop in short interest in the month of June. As of June 30th, there was short interest totaling 102,058 shares, a drop of 47.2% from the June 15th total of 193,285 shares. Currently, 2.4% of the company’s stock are short sold. Based on an average daily trading volume, of 212,492 shares, the days-to-cover ratio is presently 0.5 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Cyclacel Pharmaceuticals Stock Performance

BGMS stock traded down $0.01 during midday trading on Wednesday, reaching $0.90. 25,708 shares of the company were exchanged, compared to its average volume of 1,145,566. The company has a market cap of $4.96 million, a price-to-earnings ratio of -0.20 and a beta of -0.38. Cyclacel Pharmaceuticals has a 1-year low of $0.57 and a 1-year high of $19.87. The stock’s 50-day simple moving average is $0.93 and its 200 day simple moving average is $1.05.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last issued its earnings results on Thursday, May 14th. The company reported ($0.04) earnings per share (EPS) for the quarter. The firm had revenue of $0.78 million for the quarter.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.